Why you should care about the shakeup at NIH: Sean Morrison, Ken Covinsky, Stacy Fischer
GeriPal - A Geriatrics and Palliative Medicine Podcast
Release Date: 06/18/2026
GeriPal - A Geriatrics and Palliative Medicine Podcast
Can we prevent age-related cognitive decline, and perhaps even head off Alzheimer’s disease and related dementias before they start? Pharmaceutical companies are spending billions searching for a magic bullet pill to answer that question. But what if the solution requires more than a single drug? What if real prevention demands a multi-domain approach that combines targeted diet, exercise, social engagement, and vascular risk factor management among other things? On today’s episode, we explore multi-domain interventions for cognitive risk reduction with two leading experts: Laura D....
info_outlineGeriPal - A Geriatrics and Palliative Medicine Podcast
In 1987, lovastatin became the first FDA-approved statin in the United States. Four decades later, statins are among the most frequently prescribed medications nationwide, with atorvastatin topping the overall list. Now, updated guidelines have expanded statin eligibility to cover nearly every older adult. On today’s episode, we are joined by experts Tim Anderson, Rita Redberg, and Mike Rich to discuss when to start, and when to stop, statin therapy in older adults. Topics we talk about on starting and stopping statins in older adults include: Updates and changes for statin use in older...
info_outlineGeriPal - A Geriatrics and Palliative Medicine Podcast
When you think of palliative care pharmacotherapy, you probably think about the tried-and-true mainstays of our field like morphine, haloperidol, and senna. But the landscape of palliative symptom management is rapidly evolving, with hot new drug classes and rediscovered old-school opioids (and not just buprenorphine!) On today’s episode of the GeriPal Podcast, we sit down with three expert palliative care clinical pharmacists, Max Stevenson, Alex McPherson, and Nisha Iyer, to talk about 5 hot new drugs (or rediscovered): Suzetrigine: It works for bunions (at least as well as opioids,...
info_outlineGeriPal - A Geriatrics and Palliative Medicine Podcast
Love the story Judy Solerno tells at the start of this podcast. The story is about how mapped out cases of Cholera in London in the year 1854. He was able to identify a concentration of cases near a neighborhood water pump. Simply removing the handle from the pump halted the outbreak. This is one of the earliest recorded uses of maps for public health purposes. Our guests today, Judy Salerno (President Emeritus of the ) and Lindsay Goldman (CEO of ) have done some wonderful work creating detailed, in-depth, interactive maps of aging in New York City. Go to and try it...
info_outlineGeriPal - A Geriatrics and Palliative Medicine Podcast
Just in time for respiratory virus season, this episode of the podcast breaks down essential vaccine guidance for older adults. From flu, COVID-19, and RSV to an added bonus deep dive into shingles, we cover everything you need to know to protect older adults this season. Our expert guests include: Kenneth Schmader, MD: A geriatrician and vaccine researcher who helped develop the zoster vaccine. Ken serves on the Working Groups for the Herpes Zoster, Influenza, COVID-19, RSV and General Adult Immunization Guidelines for the US Centers for Disease Control (CDC) Advisory Committee on...
info_outlineGeriPal - A Geriatrics and Palliative Medicine Podcast
Difficulty managing money is often one of the earliest signs of Alzheimer's disease and related dementias, frequently appearing years before an official diagnosis. This loss of financial capacity leaves individuals vulnerable to costly mistakes and exploitation, threatening the financial security and quality of life of entire families. In this episode, we sit down with Dr. Lauren Hersch Nicholas, Dr. Duke Han, and Dr. Jason Karlawish to examine the intersection of cognitive decline, financial decision-making, and patient protection. We covered a lot of topics, including these key ones: The...
info_outlineGeriPal - A Geriatrics and Palliative Medicine Podcast
GLP-1 receptor agonists (the "Ozempics of the world") have been a truly revolutionary pharmacological advance in modern medicine. In randomized controlled trials (RCTs), these agents have been shown to do much more than just reduce weight, including significantly reducing cardiovascular events, lowering all-cause mortality in patients with type 2 diabetes, and even slowing the progression of chronic kidney disease. But as we see their use rapidly expand among older adults, we have to ask: at what cost? In geriatrics, weight loss is rarely simple. In older bodies, GLP1s carry increased risks,...
info_outlineGeriPal - A Geriatrics and Palliative Medicine Podcast
As Diane Meier remarks to start today’s podcast, palliative care has come a long way from the days when we were the “brink of death” consult. We’re seeing patients earlier and earlier in the course of illness. In fact, the for specialist palliative care is arguably stronger in the outpatient setting than the inpatient setting. In some ways, as Eric remarked, we are a victim of our own success. We’ve pushed on the boundaries of seeing patients earlier in the course of illness, we’ve demonstrated remarkable value to our colleagues and health systems: now they want us to see...
info_outlineGeriPal - A Geriatrics and Palliative Medicine Podcast
Up until just a couple years ago, an 85-year-old patient presenting with gradual, amnestic memory loss was almost automatically presumed to have Alzheimer’s disease. However, new biomakers and the recognition of conditions like Limbic-predominant age-related TDP-43 encephalopathy (LATE) are reshaping our understanding of cognitive decline in older adults. It’s looking more clear that pure Alzheimers dementia is rare in older adults, and co-occurring pathologies that may include Alzheimer's, LATE, Lewy Body, and vascular neuropatholigies, are the rule rather than the exception. In...
info_outlineGeriPal - A Geriatrics and Palliative Medicine Podcast
Can simple, evidence-based video decision aids—paired with structured clinician training—improve Advance Care Planning (ACP) documentation and goal-concordant care? That’s the question we pose in this week's podcast with Dr. Joshua Lakin and Dr. Kei Ouchi. We break down the methodologies behind two major clinical trials in which they were involved that implemented this video-enhanced approach. The f was a multicenter, parallel randomized trial of 598 seriously ill older adults in emergency departments (EDs). It tested whether watching a 5-minute video and having a short, 10-minute...
info_outlineEmergency Podcast! Our guests Sean Morrison, Ken Covinsky, and Stacy Fischer believe that you should care deeply about the proposed shakeup at the National Institutes of Health. Major proposed rules changes at the Office of Management and Budget, would affect a huge range of government grants, from Headstart to Transportation to the National Science Foundation, as well as the National Institutes of Health (NIH), the subject of today’s podcast.
You dear listeners should all care. You should care because you care for older adults, or you’re a researcher who studies palliative care, or you're a chaplain who visited with the family of a patient who died today. You should care because these rule changes are so sweeping that they would remove standard components of the scientific review process and instead put them in the hands of political appointees.
You should care because if rules like this were in place in the 1980s, we might not have developed treatments to stop the HIV/AIDS epidemic. You should care because if these rules go into effect we will not be able to work with researchers in other countries studying outbreaks of Ebola or Hauntavirus. You should care because these rules silence federal research into groups of people we care for daily.
And if you’re not a researcher, your voice is even more important here. As Sean says, researchers who protest these proposed rule changes might come across as self-serving. Clinicians who are not researchers - who can say that these rules will negatively impact the science that improves care of older adults living with chronic conditions and their families - your voices may resonate even more.
What can you do? Most of these rule changes are open for public comment here until July 13, 2026. Every comment will be read and requires a response. It’s ok to respond anonymously. Personalized stories matter more than form responses. Tips:
-
1: Say (or just describe to keep anonymous) who you are and why you are qualified to comment. Telling the story of how patients and families you care for or study is enough. Get your partner and parents to respond too. Simply being a concerned citizen is perfectly fine.
-
2: List the exact provision #s that concern you, and explain what they would do. You do not need to quote the rule directly. Just explain what you understand it to mean in plain terms.
-
Political Appointees Take Control of Grant Awards (§200.205);
-
Peer Review Is No Longer Binding (§200.205(d));
-
Active Grants Can Be Terminated at Any Time, for Any Reason (§200.340);
-
DEI, Gender Research, and Related Topics Banned as Grant Conditions (§200.300);
-
Prohibition on International Scientific Collaboration (§200.220);
-
Conference Attendance Now Requires Express Agency Pre-Approval (§200.432);
-
Publication Costs and Open Access Fees Presumptively Unallowable (§200.461)
-
-
3: Explain the concrete harm. What would happen to your patients and their families if this provision takes effect?
-
4: Closing: State clearly what you want OMB to do. This can be as simple as: “I urge OMB to withdraw these specific provisions: §200.340, §200.202, §200.205.” or “I urge OMB not to finalize this rule.”
Submit your comment in opposition here: The deadline is July 13, 2026. You can also email your congressperson or senator.
Times they are a changin’.